JACKSON, Miss. (WLOX) - At the 2025 Mississippi Association of Broadcasters (MAB) awards Saturday night in Jackson, WLOX took home 31 Excellence in Broadcasting awards, 11 of those being first place.

ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents ...

I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. Uliledlimab is the asset I-Mab has ...

(RTTNews) - I-Mab (IMAB) announced Thursday that Phillip Dennis has been appointed Chief Medical Officer, effective June 17, 2024. As CMO, Dennis will lead the global clinical development efforts ...

The three organisations, which Gove accused of having an "Islamist orientation", are the Muslim Association of Britain (MAB), Cage International, and Mend. Gove said: "Organisations such as the ...

Sept 22 (Reuters) - China-based biotech company I-Mab (IMAB.O), opens new tab said on Friday that AbbVie (ABBV.N), opens new tab has terminated a 2020 deal to co-develop and market I-Mab's lead ...

Image Credit: Nilsbwoy / Shutterstock.com The use of mAb treatment has been shown to reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and subsequently lead to lower ...

MAB Engineering is working toward creating a smart hangar that leverages digital capabilities and automation. Credit: Nicolas Asfouri/Getty Images The pandemic forced many aftermarket ...

Antibody-dependent cellular cytotoxicity. Image Credit: Sino Biological Inc. For several cancer types, targeted monoclonal antibody (mAb) therapy is a viable therapeutic option. Most mAbs that are ...

Shares of I-Mab IMAB were down 14.3% on Aug 17 after management disclosed in an SEC filing that the company’s partner AbbVie ABBV has decided to discontinue a phase Ib study evaluating ...